143 related articles for article (PubMed ID: 23392805)
1. TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.
Zhou DH; Yang LN; Roder C; Kalthoff H; Trauzold A
Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):94-8. PubMed ID: 23392805
[TBL] [Abstract][Full Text] [Related]
2. The potential molecular mechanism of overexpression of uPA, IL-8, MMP-7 and MMP-9 induced by TRAIL in pancreatic cancer cell.
Zhou DH; Trauzold A; Röder C; Pan G; Zheng C; Kalthoff H
Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):201-9. PubMed ID: 18397859
[TBL] [Abstract][Full Text] [Related]
3. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
4. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis.
Hinz S; Trauzold A; Boenicke L; Sandberg C; Beckmann S; Bayer E; Walczak H; Kalthoff H; Ungefroren H
Oncogene; 2000 Nov; 19(48):5477-86. PubMed ID: 11114725
[TBL] [Abstract][Full Text] [Related]
5. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
6. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.
Legler K; Hauser C; Egberts JH; Willms A; Heneweer C; Boretius S; Röcken C; Glüer CC; Becker T; Kluge M; Hill O; Gieffers C; Fricke H; Kalthoff H; Lemke J; Trauzold A
Cell Death Dis; 2018 May; 9(5):445. PubMed ID: 29670075
[TBL] [Abstract][Full Text] [Related]
7. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
8. Role of caspases in CD95L- and TRAIL-induced non-apoptotic signalling in pancreatic tumour cells.
Siegmund D; Klose S; Zhou D; Baumann B; Röder C; Kalthoff H; Wajant H; Trauzold A
Cell Signal; 2007 Jun; 19(6):1172-84. PubMed ID: 17291719
[TBL] [Abstract][Full Text] [Related]
9. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
10. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
[TBL] [Abstract][Full Text] [Related]
11. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells.
Trauzold A; Röder C; Sipos B; Karsten K; Arlt A; Jiang P; Martin-Subero JI; Siegmund D; Müerköster S; Pagerols-Raluy L; Siebert R; Wajant H; Kalthoff H
FASEB J; 2005 Apr; 19(6):620-2. PubMed ID: 15670977
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
[TBL] [Abstract][Full Text] [Related]
14. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A
J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
[TBL] [Abstract][Full Text] [Related]
15. Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells.
Willms A; Schittek H; Rahn S; Sosna J; Mert U; Adam D; Trauzold A
PLoS One; 2019; 14(4):e0214847. PubMed ID: 30947287
[TBL] [Abstract][Full Text] [Related]
16. IFN-γ combined with targeting of XIAP leads to increased apoptosis-sensitisation of TRAIL resistant pancreatic carcinoma cells.
Büneker CK; Yu R; Deedigan L; Mohr A; Zwacka RM
Cancer Lett; 2012 Mar; 316(2):168-77. PubMed ID: 22104728
[TBL] [Abstract][Full Text] [Related]
17. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
[TBL] [Abstract][Full Text] [Related]
18. Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL.
Song JJ; An JY; Kwon YT; Lee YJ
J Biol Chem; 2007 Jan; 282(1):319-28. PubMed ID: 17110373
[TBL] [Abstract][Full Text] [Related]
19. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma.
Röder C; Trauzold A; Kalthoff H
Eur J Cell Biol; 2011; 90(6-7):450-5. PubMed ID: 21129814
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma.
Hetschko H; Voss V; Horn S; Seifert V; Prehn JH; Kögel D
J Neurooncol; 2008 Feb; 86(3):265-72. PubMed ID: 17924059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
